Kalytera Therapeutics, Inc. (TSXV:KALY) announced a private placement of 6,000,000 units at CAD 0.075 per unit for gross proceeds of CAD 450,000 on January 11, 2019. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at an exercise price of CAD 0.10 per share for a period of two years from closing, subject to customary adjustments in certain events, provided that if, at any time following the date that is four months and one day from the closing date, the daily volume weighted average trading price of the common Shares equals or exceeds CAD 1 for any 10 consecutive trading days, the company may, on prior written notice, accelerate the expiry date of the warrants to the date that is 30 days following the date of such notice. All securities to be issued are subject to a statutory hold period of four months and one day from closing. The transaction is expected to close on or about January 15, 2019. The transaction is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange.